What does ImmuneWalk Therapeutics do?
ImmuneWalk Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for immune-inflammatory diseases by targeting monocyte inhibition and discovering novel adhesion checkpoints to regulate immune cell migration into inflamed tissues.
How much did they raise?
The company raised $7M in Seed financing with backing from institutional investors and participation from its management team, aiming to expand operations and enhance R&D efforts.
What are their plans for the money?
With the new funds, ImmuneWalk Therapeutics plans to accelerate its research, advance its lead candidate IW-601 through further clinical trials, and explore additional therapeutic applications, with multiple clinical catalysts expected in 2025-2026.
What have they achieved so far?
The company has demonstrated promising disease-modifying activity of IW-601 in preclinical models and has successfully completed the Single Ascending Dose stage in its POINTGUARD Phase 1 clinical trial.
